Back to News
Market Impact: 0.3
Passage Bio, Inc. Stockholders Approve Merger Proposals, Reverse Stock Split of 1-for-2 to 1-for-10, and Name Change
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechManagement & Governance
On November 5, 2026, Passage Bio stockholders approved several proposals related to the company’s merger agreement with Remix Therapeutics, including issuance of Passage Bio common stock to Remix securityholders. The available article text does not specify whether the merger has closed or provide further proposal details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
PASG0.35
More News
- Fox completes its $22B acquisition of Roku
- Paraguay’s Santiago Pena under arrest, new president Pedro Alliana sworn in
- Fox wraps up its $22 billion Roku deal
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Trump Names Miller Chief of Staff as Tech Rebounds
- How Paraguay’s Ueno collapse is only its latest banking crisis